X4 Pharmaceuticals Inc (XFOR)
0.5489
-0.02
(-2.76%)
USD |
NASDAQ |
Jul 05, 16:00
0.568
+0.02
(+3.48%)
Pre-Market: 09:06
X4 Pharmaceuticals Research and Development Expense (TTM): 69.81M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 69.81M |
| December 31, 2023 | 72.02M |
| September 30, 2023 | 75.76M |
| June 30, 2023 | 70.79M |
| March 31, 2023 | 69.01M |
| December 31, 2022 | 61.06M |
| September 30, 2022 | 54.21M |
| June 30, 2022 | 53.28M |
| March 31, 2022 | 52.66M |
| December 31, 2021 | 50.65M |
| September 30, 2021 | 50.78M |
| June 30, 2021 | 48.98M |
| March 31, 2021 | 45.12M |
| December 31, 2020 | 41.93M |
| Date | Value |
|---|---|
| September 30, 2020 | 36.70M |
| June 30, 2020 | 33.91M |
| March 31, 2020 | 33.42M |
| December 31, 2019 | 30.16M |
| September 30, 2019 | 16.81M |
| June 30, 2019 | 17.79M |
| March 31, 2019 | 17.87M |
| December 31, 2018 | 20.35M |
| September 30, 2018 | 35.86M |
| June 30, 2018 | 36.89M |
| March 31, 2018 | 31.87M |
| December 31, 2017 | 28.13M |
| September 30, 2017 | 23.12M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
16.81M
Minimum
Sep 2019
75.76M
Maximum
Sep 2023
50.90M
Average
50.78M
Median
Sep 2021
Research and Development Expense (TTM) Benchmarks
| Amgen Inc | 5.069B |
| Ironwood Pharmaceuticals Inc | 129.05M |
| Ocular Therapeutix Inc | 67.04M |
| Scholar Rock Holding Corp | 135.26M |
| RAPT Therapeutics Inc | 100.21M |